Trial Profile
A 24-week, Multicenter, Randomized, Open-Label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BRIGHT
- Sponsors Sanofi
- 01 Jul 2021 Results of subanalysis assessing efficacy and safety of Gla-300 versus IDeg-100 in predefined (less than or greater than equal to 65 years) and post hoc (less than or greater than equal to 70 years) age group with type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
- 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 06 Dec 2019 Results of post-hoc analysis assessing HbA1c change and incidence and rates of hypoglycaemia presented at the 2019 Congress of the International Diabetes Federation.